Additional Hetero Ring Patents (Class 514/202)
  • Patent number: 9751894
    Abstract: Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or both of a terminal amidine residue (substituted or unsubstituted) attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain, or a terminal guanidine residue attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: September 5, 2017
    Assignee: NAEJA-RGM PHARMACEUTICALS INC.
    Inventors: Samarendra Nath Maiti, Dai Quoc Nguyen, Andhe V. N. Reddy, Judy Yip, Chan Minh Ha, Rong Ling, Rudong Shan, Madhava Reddy Madala
  • Patent number: 9695196
    Abstract: This disclosure relates to an improved synthesis of cephalosporin antibiotic compounds such as ceftolozane, and compositions and methods of use thereof. Thiadiazolyl-oximinoacetic acid compounds such as TATD can be reacted to yield the activated thiadiazolyl-oximinoacetic acid methanesulfonate ester compounds useful in the manufacture of cephalosporin antibiotic compounds.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: July 4, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kristos Adrian Moshos, Valdas Jurkauskas, Manuel Scanu, Michele Benotti
  • Patent number: 9661850
    Abstract: The present invention relates to methods of controlling and/or preventing soil-dwelling pests in useful plants comprising applying to the locus of the useful plant or treating plant propagation material thereof with a compound of formula (I) wherein —B1—B2—B3— is —C?N—O—, —C?N—CH2—, —C?CH2—O— or —N—CH2—CH2—; L is a direct bond or methylene; A1 and A2 are C—H, or one of A1 and A2 is C—H and the other is N; X1 is group X, formula (X) R1 is C1-C4alkyl, C1-C4aloalkyl or C3-C6cycloalkyl; R2 is chlorodifluoromethyl or trifluoromethyl; each R3 is independently bromo, chloro, fluoro or trifluoromethyl; R4 is hydrogen, halogen, methyl, halomethyl or cyano; R5 is hydrogen; or R4 and R5 together form a bridging 1,3-butadiene group; p is 2 or 3. Preferably the soil-dwelling pest is selected from corn rootworm, wireworms, grubs, in particular white grubs (e.g. Phyllophaga sp., Diloboderus sp., Popillia japonica), termites (in particular for sugar cane), subterraneous stinkbugs (e.g. Scaptocoris sp.), cutworms (e.g.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: May 30, 2017
    Assignee: Syngenta Participations AG
    Inventors: Myriem El Qacemi, Jerome Yves Cassayre, Benedikt Kurtz
  • Patent number: 9476883
    Abstract: Disclosed are conjugates that can bind to one or more site on cancer cell surface, for example, surface proteins, compound specific receptors and carbohydrates that comprise the surface of specific cell types. The disclosed conjugates can thereby serve as indicators identifying the presence of cancerous tissue.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: October 25, 2016
    Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Chaofeng Dai, Binghe Wang, Lifang Wang, Yong Chu
  • Patent number: 9334289
    Abstract: The present invention provides a novel compound which has a wide antimicrobial spectrum, and in particular exhibits potent antimicrobial activity against beta-lactamase producing Gram negative bacteria. Specifically, the present invention provides a compound of the formula (I): wherein each symbol is as defined in the specification, or an amino-protected compound when the amino group is present on the ring in the 7-side chain, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: May 10, 2016
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yasuhiro Nishitani, Toshiaki Aoki, Jun Sato, Kenji Yamawaki, Katsuki Yokoo, Masayuki Sano
  • Patent number: 9238657
    Abstract: The present disclosure describes Cephem compounds of the formula: wherein, X is N, CH or C—Cl; T is S or the like; A and G are lower alkylene or the like; B is a single bond or the like; D is optionally present, and when present is, —NR7—, —CO—, —CO—NR7—, —NR7—CO—, —NR7—CO—NR7—, or the like; F is optionally present, and when present is or phenylene; R3 and R4 are —OR8; R5 and R6 each is independently hydrogen, halogen, nitrile, or —OR8; or an ester at the carboxyl at the 7-position side chain or at the 4-position, a compound protected at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof, which have a wide antimicrobial spectrum and have potent antimicrobial activity against beta-lactamase producing Gram negative bacteria.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: January 19, 2016
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yasuhiro Nishitani, Kenji Yamawaki, Yusuke Takeoka, Hideki Sugimoto, Shinya Hisakawa, Toshiaki Aoki
  • Patent number: 9211262
    Abstract: Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilized powder with a carrier selected from lactose and dextran, mixed with sodium chloride.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: December 15, 2015
    Assignee: CTI BioPharma Corp.
    Inventors: Alberto Bernareggi, Valeria Livi
  • Patent number: 9145425
    Abstract: This invention provides Cephem compounds having the formula: or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof, a pharmaceutical composition thereof, and a method for treating a bacterial infectious disease with the compound, the ester, the protected compound, the salt, or the solvate thereof, wherein the symbols in the formula are defined in the specification. The compounds exhibit potent antimicrobial spectrum against a variety of bacteria including Gram negative bacteria and/or Gram positive bacteria, preferably beta-lactamase producing Gram negative bacteria, more preferably, multi-drug resistant microbials, in particular, Class B type metallo-beta-lactamase producing Gram negative bacteria, and still preferably extended-spectrum beta-lactamase (ESBL) producing bacteria. The compounds most preferably do not exhibit cross-resistance against known Cephem drugs or Carbapenem drugs.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: September 29, 2015
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shinya Hisakawa, Yasushi Hasegawa, Toshiaki Aoki, Hiroki Kusano, Masayuki Sano, Jun Sato, Kenji Yamawaki
  • Patent number: 9044485
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: June 2, 2015
    Assignee: CALIXA THERAPEUTICS, INC.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Yanmei Lan, Jonathan Cam Ly, Jianxun Zhou
  • Publication number: 20150140111
    Abstract: The invention relates to effervescent pharmaceutical dosage forms including cefdinir as the active agent, and their preparation. The invention also relates to effervescent formulations including ceftibuten and/or its pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof. The invention also relates to pharmaceutical compositions including (Z)-3-Carboxymethyl-7-(2-(2-furyl)-2-methoxyiminoacetylamino)-3-sefem-4-carboxylic acid which is named cefuroxime axetil or any pharmaceutically acceptable derivative thereof, and the use of these compositions in the treatment of bacterial infections. Lastly, the invention relates to pharmaceutical formulations including a third generation cephalosporin together with clavulanic acid and/or derivatives thereof as the active agents.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 21, 2015
    Inventor: Mahmut BILGIC
  • Publication number: 20150111853
    Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 23, 2015
    Inventors: Jan-Ji Lai, Pradip M. Pathare, Laxma Kolla, Adrien F. Soret
  • Publication number: 20150111864
    Abstract: This disclosure provides compositions containing solid forms of (2S,5R)-2-(5-(3-aminopropyl)-1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate, and methods of manufacturing and using these compositions.
    Type: Application
    Filed: October 2, 2014
    Publication date: April 23, 2015
    Inventors: Sudhakar Garad, Akash Jain, You Seok Hwang
  • Patent number: 8969570
    Abstract: Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit ?-lactamases of class A, class C or class D and potentiate ?-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a ?-lactam antibiotic at a fixed concentration have an MIC of 8 ?g/mL or less against one or more isogenic ?-lactamase expressing bacterial strains.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: March 3, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Robert Busch, Roland E. Dolle, Chester A. Metcalf, III
  • Patent number: 8962843
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: February 24, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III
  • Patent number: 8962844
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: February 24, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Dongpeng Wan
  • Publication number: 20150045338
    Abstract: This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.
    Type: Application
    Filed: October 13, 2014
    Publication date: February 12, 2015
    Inventors: Gurudatt A. Chandorkar, Jennifer A. Huntington, Tara Parsons, Obiamiwe C. Umeh
  • Publication number: 20150038478
    Abstract: Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit ?-lactamases of class A, class C or class D and potentiate ?-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a ?-lactam antibiotic at a fixed concentration have an MIC of 8 ?g/mL or less against one or more isogenic ?-lactamase expressing bacterial strains.
    Type: Application
    Filed: October 2, 2014
    Publication date: February 5, 2015
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Robert Busch
  • Publication number: 20150038479
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: October 2, 2014
    Publication date: February 5, 2015
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch
  • Publication number: 20150031659
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 29, 2015
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch
  • Publication number: 20150031660
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 29, 2015
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch
  • Patent number: 8940897
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III
  • Publication number: 20150017099
    Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 15, 2015
    Inventors: Noam A. Cohen, Robert J. Lee, Danielle R. Reed
  • Patent number: 8933233
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: January 13, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III
  • Patent number: 8933232
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: January 13, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III
  • Patent number: 8933068
    Abstract: A diluted solution of ceftiofur sodium is intrathecally or ventricularly delivered to effectively treat bacterial meningitis while maintaining the patient's threshold and reducing the likelihood of seizure.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: January 13, 2015
    Assignee: NBR Pathfinder LLC
    Inventor: Robert B. Boyd
  • Publication number: 20150011524
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Inventors: Larry SUTTON, Sophia YU
  • Patent number: 8927724
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: January 6, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch, Dongpeng Wan, Jon Christian Baber
  • Patent number: 8916709
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: December 23, 2014
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Jon Christian Baber
  • Publication number: 20140343003
    Abstract: The present invention provides a method for treating Lyme disease and/or a Borrelia infection in animals comprising administering to an animal in need thereof a therapeutically effective amount of cefovecin.
    Type: Application
    Filed: December 20, 2012
    Publication date: November 20, 2014
    Inventors: Patrick F. M. Meeus, Christopher L. Haber
  • Patent number: 8883772
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Compounds of the invention include those of formula: and pharmacologically acceptable salts thereof where variables Z, Y, M, y, n, R, R4, R5, R1 and R2 are as defined in the specification. M most generally represents a chemical moiety which is in conjugation with the nitrogen of the core beta-lactam ring system of the compound, such that one or more reactive species, e.g., electrophilic or nucleophilic sites are generated on modification of M which is initiated by cleavage of the beta-lactam ring. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: November 11, 2014
    Assignee: Sopharmia, Inc.
    Inventors: Larry Sutton, Sophia Yu
  • Publication number: 20140329777
    Abstract: Methods to treat infectious diseases are disclosed herein. Some embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) to treat infectious diseases. Other embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) and administration of one or more antibiotics to treat infectious diseases.
    Type: Application
    Filed: April 22, 2014
    Publication date: November 6, 2014
    Inventors: Lisa Ann Morici, Saja Asakrah
  • Publication number: 20140329793
    Abstract: The invention features pharmaceutical compositions including (i) a drug, and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug.
    Type: Application
    Filed: October 19, 2012
    Publication date: November 6, 2014
    Applicant: SEACHAID PHARMACEUTICALS, INC.
    Inventors: Balasingam Radhakrishnan, Anuradha Vaidya, Navdeep Balkrishna Malkar, Karen Polowy, Kenneth Duke James, JR.
  • Publication number: 20140323459
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: April 23, 2014
    Publication date: October 30, 2014
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch
  • Publication number: 20140274992
    Abstract: Pharmaceutical formulations can include ceftolozane and an alkalizing agent such as L-arginine.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Nicole Miller Damour, Jacqueline Marie Walsh, Joseph Terracciano
  • Publication number: 20140274925
    Abstract: Disclosed herein are compositions and methods for diagnosing, treating, and monitoring Lyme disease.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventors: Chenggang Jin, Gottfried H. Kellermann
  • Publication number: 20140274958
    Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Jan-Ji Lai, Pradip M. Pathare, Laxma Kolla, Adrien F. Soret
  • Publication number: 20140274997
    Abstract: Pharmaceutical compositions including a cephalosporin disclosed herein as having the structure of formula (III).
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Jianxun Zhou, Nicole Miller Damour, Yanmei Lan, Jonathan Cam Ly, Joseph Terracciano
  • Publication number: 20140274990
    Abstract: Pharmaceutical compositions can include an amount of sodium chloride effective to stabilize ceftolozane in a lyophilized formulation.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20140274999
    Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Jan-Ji Lai, Pradip M. Pathare, Laxma Kolla, Adrien F. Soret
  • Publication number: 20140275000
    Abstract: Pharmaceutical compositions can include an amount of sodium chloride effective to stabilize ceftolozane in an antibiotic formulation.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Nicole Miller Damour, Joseph Terracciano
  • Publication number: 20140274994
    Abstract: Pharmaceutical compositions can include an amount of a ceftolozane and a stabilizing agent in a formulation for parenteral administration.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventor: Nicole Miller Damour
  • Patent number: 8835376
    Abstract: A process for making particles for delivery of drug nanoparticles is disclosed herein. The process comprises the steps of (a) forming a suspension of drug nanoparticles by mixing a precipitant solution with an anti-solvent solution under micro-mixing environment, where the formed nanoparticles have a narrow particle size distribution; (b) providing an excipient to at least one of the precipitant solution, the anti-solvent solution and the suspension of drug nanoparticles, the excipient being selected to maintain said drug nanoparticles in a dispersed state when in liquid form; and (c) drying the suspension of drug nanoparticles containing the excipient therein to remove solvent therefrom, wherein removal of the solvent causes the excipient to solidify and thereby form micro-sized matrix particles, each micro-sized particle being comprised of drug nanoparticles dispersed in a solid matrix of the excipient.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: September 16, 2014
    Assignee: Nanomaterials Technology Pte Ltd
    Inventors: Zhigang Shen, Jimmy Sung Lai Yun, Jun Hu, Nital Arvind Jugade, Jiyao Zhang, Wenhao Chen, Zhe Wang, Lingyan Gao, William Glover, Jian Feng Chen
  • Publication number: 20140256697
    Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof wherein A represents a group represented by one of formulae (i)-(iii); B represents a group represented by formula (v) or (vi); and E represents a substituted or unsubstituted heterocyclic group having a cationic nitrogen atom.
    Type: Application
    Filed: October 3, 2012
    Publication date: September 11, 2014
    Inventors: Kenji Yamawaki, Masayuki Sano, Jun Sato
  • Publication number: 20140256616
    Abstract: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicant: Georgia Regents Research Institute, Inc.
    Inventor: Stephen D. Hsu
  • Publication number: 20140249126
    Abstract: The present invention relates to cephalosporin antibacterial compounds of Formula (I): or corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.
    Type: Application
    Filed: October 4, 2012
    Publication date: September 4, 2014
    Inventors: Xiangmin Liao, Neil David Pearson, Israil Pendrak, Masayuki Sano
  • Publication number: 20140235533
    Abstract: The present invention provides compounds of formula I wherein Q is Q1 or Q2; A1, A2, A3 and A4 are independently of each other C—H, C—R7, or nitrogen; R1 is C1-C8haloalkyl; R2 is aryl or aryl substituted by one to five R11, or heteroaryl or heteroaryl substituted by one to five R11; and R3, R4, R5, R6 and R7 are as defined in the claims. The invention also provides methods of controlling insects, acarines, nematodes or molluscs which methods comprise applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound of formula (I).
    Type: Application
    Filed: August 10, 2012
    Publication date: August 21, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Tomas Smejkai, Sebastian Volker Wendeborn, Jerome Yves Cassayre, Myriem El Qacemi, Bernhard Breit, Lisa Diab, Regis Jean Georges Mondiere
  • Publication number: 20140221331
    Abstract: The present invention relates generally to methods and compounds for regulating the release of nitric oxide in the vicinity of biofilm-forming microorganisms to regulate programmed cell death in the microorganisms and thereby promote dispersal of microorganism from biofilms and/or inhibit biofilm formation or development. More particularly, the invention relates to the use of compounds to provide spatial and temporal control over nitric oxide release.
    Type: Application
    Filed: May 16, 2012
    Publication date: August 7, 2014
    Applicants: UNIVERSITY OF WOLLONGONG, NEWSOUTH INNOVATIONS PTY LIMITED
    Inventors: Nicolas Barraud, Bharat Gangadhar Kardak, Michael John Kelso, Staffan Kjelleberg, Scott Rice
  • Publication number: 20140171401
    Abstract: A chewable tablet comprising Cefixime having a mean particle size between 20? and 120? wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20? and 120?, blending with other excipients, roll compaction, milling to form granules, blending to form a secondary blend and compression of the secondary blend to form tablets.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: LUPIN LTD.
    Inventors: Sanjay WAGH, Hidaytulla AGA, Makarand AVACHAT, Himadri SEN
  • Patent number: 8735362
    Abstract: The present invention relates to compounds of formula (I): Wherein A1, A2, A3, A4, G1, L, Y1, Y2, Y3, Y4, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to intermediates for preparing compounds of formula (I), to compositions comprising them and to methods of using them to combat and control insect, acarine, nematode and mollusc pests.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: May 27, 2014
    Assignee: Syngenta Crop Protection, LLC
    Inventors: Jerome Yves Cassayre, Peter Renold, Myriem El Qacemi, Thomas Pitterna, Julie Clementine Toueg
  • Publication number: 20140128335
    Abstract: The present invention relates to the use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment of bacteria including those presenting multiple drug resistance (MDR), in particular as efflux pump inhibitors. It also relates to novel polyaminoisoprenyl derivatives, compositions comprising the same, process for preparing the same, and use thereof in antibiotic or antiseptic treatment.
    Type: Application
    Filed: February 23, 2012
    Publication date: May 8, 2014
    Applicants: UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE DE CORSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Michel Bolla, Jean Michel Brunel, Joseph Pierre Felix Casanova, Vannina Lorenzi, Liliane Berti